Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments.
Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments.
复制标题
DOI：
10.1002/pon.3409
复制
发表时间：
2014-02
期刊：
影响因子：
3.6
通讯作者：
Verdonck-de Leeuw, I. M.
中科院分区：
文献类型：
--
作者：
Krebber, A. M. H.;Buffart, L. M.;Kleijn, G.;Riepma, I. C.;de Bree, R.;Leemans, C. R.;Becker, A.;Brug, J.;van Straten, A.;Cuijpers, P.;Verdonck-de Leeuw, I. M.
我们的目的是通过诊断访谈和自我报告工具来调查癌症患者的抑郁患病率，并研究工具类型、癌症类型和治疗阶段之间患病率的差异。在四个数据库中进行文献检索，以选择成年癌症患者在治疗期间或治疗后抑郁患病率的研究。共有211项研究符合纳入标准。使用综合meta分析计算合并平均抑郁症患病率。医院焦虑和抑郁量表-抑郁子量表(HADS-D)≥8,HADS-D≥11，流行病学研究中心≥16，以及（半）结构化诊断访谈分别在66、53、35和49项研究中用于定义抑郁症。各自的意思是抑郁症的患病率为17% (95% CI = 16 - 19%), 8% (95% CI = 7 - 9%), 24% (95% CI = 21 - 26%)和13% (95% CI = 11 - 15%) (p < 0.001)。根据诊断性访谈，抑郁症的患病率从肺癌患者的3%到消化道癌症患者的31%不等。治疗期间抑郁症的患病率最高，通过诊断访谈测量为14% (95% CI = 11-17%)，通过自我报告工具测量为27% （95% CI = 25-30%）。在诊断后的第一年，用诊断访谈和自我报告工具测量的抑郁症患病率分别为9% （95% CI = 7-11%）和21% (95% CI = 19-24%)，在诊断后≥1年分别为8% （95% CI = 5-12%）和15% （95% CI = 13-17%）。癌症患者抑郁的综合平均患病率从8%到24%不等，因治疗工具类型、癌症类型和治疗阶段而异。未来的前瞻性研究应该弄清楚抑郁症患病率的差异是否由工具类型、癌症类型或治疗阶段的差异引起。
We aimed to investigate the prevalence of depression in cancer patients assessed by diagnostic interviews and self-report instruments, and to study differences in prevalence between type of instrument, type of cancer and treatment phase. A literature search was conducted in four databases to select studies on the prevalence of depression among adult cancer patients during or after treatment. A total of 211 studies met the inclusion criteria. Pooled mean prevalence of depression was calculated using Comprehensive Meta-Analysis. Hospital Anxiety and Depression Scale—depression subscale (HADS-D) ≥ 8, HADS-D ≥11, Center for Epidemiologic Studies ≥ 16, and (semi-)structured diagnostic interviews were used to define depression in 66, 53, 35 and 49 studies, respectively. Respective mean prevalence of depression was 17% (95% CI = 16–19%), 8% (95% CI = 7–9%), 24% (95% CI = 21–26%), and 13% (95% CI = 11–15%) (p < 0.001). Prevalence of depression ranged from 3% in patients with lung cancer to 31% in patients with cancer of the digestive tract, on the basis of diagnostic interviews. Prevalence of depression was highest during treatment 14% (95% CI = 11–17%), measured by diagnostic interviews, and 27% (95% CI = 25–30%), measured by self-report instruments. In the first year after diagnosis, prevalence of depression measured with diagnostic interviews and self-report instruments were 9% (95% CI = 7–11%) and 21% (95% CI = 19–24%), respectively, and they were 8% (95% CI = 5–12%) and 15% (95% CI = 13–17%) ≥ 1 year after diagnosis. Pooled mean prevalence of depression in cancer patients ranged from 8% to 24% and differed by the type of instrument, type of cancer and treatment phase. Future prospective studies should disentangle whether differences in prevalence of depression are caused by differences in the type of instrument, type of cancer or treatment phase.
登录
查看更多内容
影响因子：
6.6
作者：
Mitchell, Alex J.;Meader, Nick;Zabora, James
通讯作者：
Zabora, James
影响因子：
3.6
作者：
Lam, Wendy W. T.;Bonanno, George A.;Fielding, Richard
通讯作者：
Fielding, Richard
影响因子：
120.7
作者：
DEROGATIS, LR;MORROW, GR;CARNICKE, CLM
通讯作者：
CARNICKE, CLM
DOI：
10.1111/j.1440-1614.2004.01358.x
发表时间：
2004-05-01
影响因子：
4.6
作者：
Kissane, DW;Grabsch, B;Smith, GC
通讯作者：
Smith, GC
影响因子：
3.4
作者：
McCaffrey, Judith Czaja;Weitzner, Michael;Booth-Jones, Margaret
通讯作者：
Booth-Jones, Margaret